Drug recall · June 7, 2023
Tobramycin Inhalation Solution USP recall
Why: CGMP Deviations: Firm went out of business and could no longer continue stability studies.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Tobramycin Inhalation Solution USP, 300 mg/5 mL, 4 single-dose ampules, Rx only, Manufactured by: Akorn, Inc, Lake Forest, IL 60045. ALL NDCs
- Lots / codes
All Lots
- Quantity
- N/A
- Company
- Akorn, Inc., Gurnee, IL
- Distribution
- Nationwide in the USA and Puerto Rico
- Initiated
- April 26, 2023 · Voluntary: Firm initiated
- Classified
- June 1, 2023
- Reported
- June 7, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Tobramycin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.